Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Dürig J[au]:

Search results

Items: 1 to 50 of 181

1.

Human multipotent hematopoietic progenitor cell expansion is neither supported in endothelial and endothelial/mesenchymal co-cultures nor in NSG mice.

Radtke S, Görgens A, da Conceição Castro SV, Kordelas L, Köninger A, Dürig J, Möllmann M, Horn PA, Giebel B.

Sci Rep. 2019 Sep 9;9(1):12914. doi: 10.1038/s41598-019-49221-x.

3.

Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma.

Merz M, Hielscher T, Mai EK, Seckinger A, Hose D, Jauch A, Sauer S, Luntz S, Bertsch U, Raab MS, Neben K, Salwender H, Blau IW, Lindemann HW, Dürig J, Scheid C, Haenel M, Weisel K, Weber T, Delorme S, Goldschmidt H, Hillengass J.

Blood Cancer J. 2019 Aug 27;9(9):71. doi: 10.1038/s41408-019-0235-3. No abstract available.

4.

Cereblon-binding proteins expression levels correlate with hyperdiploidy in newly diagnosed multiple myeloma patients.

Kriegsmann K, Baertsch MA, Awwad MHS, Merz M, Hose D, Seckinger A, Jauch A, Becker N, Benner A, Raab MS, Hillengass J, Bertsch U, Dürig J, Salwender HJ, Hänel M, Fenk R, Munder M, Weisel K, Müller-Tidow C, Goldschmidt H, Hundemer M.

Blood Cancer J. 2019 Jan 29;9(2):13. doi: 10.1038/s41408-019-0174-z.

5.

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.

Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, Schroers R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nückel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U.

Ann Hematol. 2019 Apr;98(4):897-907. doi: 10.1007/s00277-018-3578-0. Epub 2019 Jan 4.

PMID:
30610279
6.

The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma.

Awwad MHS, Kriegsmann K, Plaumann J, Benn M, Hillengass J, Raab MS, Bertsch U, Munder M, Weisel K, Salwender HJ, Hänel M, Fenk R, Dürig J, Müller-Tidow C, Goldschmidt H, Hundemer M.

Oncoimmunology. 2018 Aug 1;7(10):e1486356. doi: 10.1080/2162402X.2018.1486356. eCollection 2018.

7.

Notch2 controls non-autonomous Wnt-signalling in chronic lymphocytic leukaemia.

Mangolini M, Götte F, Moore A, Ammon T, Oelsner M, Lutzny-Geier G, Klein-Hitpass L, Williamson JC, Lehner PJ, Dürig J, Möllmann M, Rásó-Barnett L, Hughes K, Santoro A, Méndez-Ferrer S, Oostendorp RAJ, Zimber-Strobl U, Peschel C, Hodson DJ, Schmidt-Supprian M, Ringshausen I.

Nat Commun. 2018 Sep 21;9(1):3839. doi: 10.1038/s41467-018-06069-5.

8.

New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance.

Pflug N, Cramer P, Robrecht S, Bahlo J, Westermann A, Fink AM, Schrader A, Mayer P, Oberbeck S, Seiler T, Zenz T, Dürig J, Kreuzer KA, Stilgenbauer S, Eichhorst B, Hallek M, Herling M, Hopfinger G.

Leuk Lymphoma. 2019 Mar;60(3):649-657. doi: 10.1080/10428194.2018.1488253. Epub 2018 Sep 20.

PMID:
30234404
9.

Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.

Leeksma AC, Taylor J, Wu B, Gardner JR, He J, Nahas M, Gonen M, Alemayehu WG, Te Raa D, Walther T, Hüllein J, Dietrich S, Claus R, de Boer F, de Heer K, Dubois J, Dampmann M, Dürig J, van Oers MHJ, Geisler CH, Eldering E, Levine RL, Miller V, Mughal T, Lamanna N, Frattini MG, Heaney ML, Zelenetz A, Zenz T, Abdel-Wahab O, Kater AP.

Leukemia. 2019 Feb;33(2):390-402. doi: 10.1038/s41375-018-0215-9. Epub 2018 Jul 23.

10.

Potent anti-leukemic activity of a specific cyclin-dependent kinase 9 inhibitor in mouse models of chronic lymphocytic leukemia.

Göthert JR, Imsak R, Möllmann M, Kesper S, Göbel M, Dührsen U, Scholz A, Lücking U, Baumann M, Unger A, Schultz-Fademrecht C, Klebl B, Eickhoff J, Choidas A, Dürig J.

Oncotarget. 2018 May 29;9(41):26353-26369. doi: 10.18632/oncotarget.25293. eCollection 2018 May 29.

11.

Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.

Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE.

J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1.

PMID:
29856692
12.

Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial.

Dührsen U, Müller S, Hertenstein B, Thomssen H, Kotzerke J, Mesters R, Berdel WE, Franzius C, Kroschinsky F, Weckesser M, Kofahl-Krause D, Bengel FM, Dürig J, Matschke J, Schmitz C, Pöppel T, Ose C, Brinkmann M, La Rosée P, Freesmeyer M, Hertel A, Höffkes HG, Behringer D, Prange-Krex G, Wilop S, Krohn T, Holzinger J, Griesshammer M, Giagounidis A, Raghavachar A, Maschmeyer G, Brink I, Bernhard H, Haberkorn U, Gaska T, Kurch L, van Assema DME, Klapper W, Hoelzer D, Geworski L, Jöckel KH, Scherag A, Bockisch A, Rekowski J, Hüttmann A; PETAL Trial Investigators.

J Clin Oncol. 2018 Jul 10;36(20):2024-2034. doi: 10.1200/JCO.2017.76.8093. Epub 2018 May 11.

PMID:
29750632
13.

Light chain monoclonal gammopathy of undetermined significance is characterized by a high disappearance rate and low risk of progression on longitudinal analysis.

Pelzer BW, Arendt M, Moebus S, Eisele L, Jöckel KH, Dührsen U, Dürig J; Heinz Nixdorf Recall Study Investigative Group.

Ann Hematol. 2018 Aug;97(8):1463-1469. doi: 10.1007/s00277-018-3305-x. Epub 2018 Apr 9.

PMID:
29629484
14.

SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia.

Johansson P, Klein-Hitpass L, Choidas A, Habenberger P, Mahboubi B, Kim B, Bergmann A, Scholtysik R, Brauser M, Lollies A, Siebert R, Zenz T, Dührsen U, Küppers R, Dürig J.

Blood Cancer J. 2018 Jan 19;8(1):11. doi: 10.1038/s41408-017-0036-5.

15.

Successful treatment of cerebral aspergillosis: case report of a patient with T-cell large granular lymphocytic leukemia (T-LGL).

Turki AT, Rashidi-Alavijeh J, Dürig J, Gerken G, Rath PM, Witzke O.

BMC Infect Dis. 2017 Dec 28;17(1):797. doi: 10.1186/s12879-017-2877-8.

16.

Biased IGH VDJ gene repertoire and clonal expansions in B cells of chronically hepatitis C virus-infected individuals.

Tucci FA, Kitanovski S, Johansson P, Klein-Hitpass L, Kahraman A, Dürig J, Hoffmann D, Küppers R.

Blood. 2018 Feb 1;131(5):546-557. doi: 10.1182/blood-2017-09-805762. Epub 2017 Dec 14.

PMID:
29242186
17.

Drug-perturbation-based stratification of blood cancer.

Dietrich S, Oleś M, Lu J, Sellner L, Anders S, Velten B, Wu B, Hüllein J, da Silva Liberio M, Walther T, Wagner L, Rabe S, Ghidelli-Disse S, Bantscheff M, Oleś AK, Słabicki M, Mock A, Oakes CC, Wang S, Oppermann S, Lukas M, Kim V, Sill M, Benner A, Jauch A, Sutton LA, Young E, Rosenquist R, Liu X, Jethwa A, Lee KS, Lewis J, Putzker K, Lutz C, Rossi D, Mokhir A, Oellerich T, Zirlik K, Herling M, Nguyen-Khac F, Plass C, Andersson E, Mustjoki S, von Kalle C, Ho AD, Hensel M, Dürig J, Ringshausen I, Zapatka M, Huber W, Zenz T.

J Clin Invest. 2018 Jan 2;128(1):427-445. doi: 10.1172/JCI93801. Epub 2017 Dec 11.

18.

Inhibitors of the Diadenosine Tetraphosphate Phosphorylase Rv2613c of Mycobacterium tuberculosis.

Götz KH, Hacker SM, Mayer D, Dürig JN, Stenger S, Marx A.

ACS Chem Biol. 2017 Oct 20;12(10):2682-2689. doi: 10.1021/acschembio.7b00653. Epub 2017 Sep 26.

PMID:
28892605
19.

Is long-term particulate matter and nitrogen dioxide air pollution associated with incident monoclonal gammopathy of undetermined significance (MGUS)? An analysis of the Heinz Nixdorf Recall study.

Orban E, Arendt M, Hennig F, Lucht S, Eisele L, Jakobs H, Dürig J, Hoffmann B, Jöckel KH, Moebus S.

Environ Int. 2017 Nov;108:237-245. doi: 10.1016/j.envint.2017.08.007. Epub 2017 Sep 5.

PMID:
28886417
20.

Tumor-derived exosomes modulate PD-L1 expression in monocytes.

Haderk F, Schulz R, Iskar M, Cid LL, Worst T, Willmund KV, Schulz A, Warnken U, Seiler J, Benner A, Nessling M, Zenz T, Göbel M, Dürig J, Diederichs S, Paggetti J, Moussay E, Stilgenbauer S, Zapatka M, Lichter P, Seiffert M.

Sci Immunol. 2017 Jul 28;2(13). pii: eaah5509. doi: 10.1126/sciimmunol.aah5509.

PMID:
28754746
21.

Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial.

Huhn S, Weinhold N, Nickel J, Pritsch M, Hielscher T, Hummel M, Bertsch U, Huegle-Doerr B, Vogel M, Angermund R, Hänel M, Salwender HJ, Weisel K, Dürig J, Görner M, Kirchner H, Peter N, Graeven U, Lordick F, Hoffmann M, Reimer P, Blau IW, Jauch A, Dembowsky K, Möhler T, Wuchter P, Goldschmidt H.

Bone Marrow Transplant. 2017 Aug;52(8):1194-1198. doi: 10.1038/bmt.2017.91. Epub 2017 May 15. No abstract available.

22.

HLA-E allelic genotype correlates with HLA-E plasma levels and predicts early progression in chronic lymphocytic leukemia.

Wagner B, da Silva Nardi F, Schramm S, Kraemer T, Celik AA, Dürig J, Horn PA, Dührsen U, Nückel H, Rebmann V.

Cancer. 2017 Mar 1;123(5):814-823. doi: 10.1002/cncr.30427. Epub 2016 Nov 2.

23.

Recurrent mutations in NF-κB pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.

Johansson P, Klein-Hitpass L, Grabellus F, Arnold G, Klapper W, Pförtner R, Dührsen U, Eckstein A, Dürig J, Küppers R.

Oncotarget. 2016 Sep 20;7(38):62627-62639. doi: 10.18632/oncotarget.11548.

24.

Deorphanization and characterization of the ectopically expressed olfactory receptor OR51B5 in myelogenous leukemia cells.

Manteniotis S, Wojcik S, Göthert JR, Dürig J, Dührsen U, Gisselmann G, Hatt H.

Cell Death Discov. 2016 May 9;2:16010. doi: 10.1038/cddiscovery.2016.10. eCollection 2016.

25.

Frequency of expression and generation of T-cell responses against antigens on multiple myeloma cells in patients included in the GMMG-MM5 trial.

Schmitt M, Hückelhoven AG, Hundemer M, Schmitt A, Lipp S, Emde M, Salwender H, Hänel M, Weisel K, Bertsch U, Dürig J, Ho AD, Blau IW, Goldschmidt H, Seckinger A, Hose D.

Oncotarget. 2016 Aug 11;8(49):84847-84862. doi: 10.18632/oncotarget.11215. eCollection 2017 Oct 17.

26.

Associations of ofatumumab exposure and treatment outcomes in patients with untreated CLL receiving chemoimmunotherapy.

Jewell RC, Kipps TJ, Dürig J, Griskevicius L, Stilgenbauer S, Smolej L, Mayer J, Hess G, Hernandez-Ilizaliturri FJ, Padmanabhan-Iyer S, Fang L, Goldstein N, Gorczyca M, Gupta I, Lisby S, Wierda WG; Hx-CD20-407 Study Investigators.

Leuk Lymphoma. 2017 Feb;58(2):348-356. Epub 2016 Jul 7.

PMID:
27389174
27.

A novel LAMB2 gene mutation associated with a severe phenotype in a neonate with Pierson syndrome.

Zemrani B, Cachat F, Bonny O, Giannoni E, Durig J, Fellmann F, Chehade H.

Eur J Med Res. 2016 Apr 30;21:19. doi: 10.1186/s40001-016-0215-z.

28.

Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial.

Bühler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Dürig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S.

Blood Cancer J. 2016 Mar 11;6:e404. doi: 10.1038/bcj.2016.9.

29.

Genes encoding members of the JAK-STAT pathway or epigenetic regulators are recurrently mutated in T-cell prolymphocytic leukaemia.

López C, Bergmann AK, Paul U, Murga Penas EM, Nagel I, Betts MJ, Johansson P, Ritgen M, Baumann T, Aymerich M, Jayne S, Russell RB, Campo E, Dyer MJ, Dürig J, Siebert R.

Br J Haematol. 2016 Apr;173(2):265-73. doi: 10.1111/bjh.13952. Epub 2016 Feb 25.

PMID:
26917488
30.

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial.

Wendtner CM, Hallek M, Fraser GA, Michallet AS, Hillmen P, Dürig J, Kalaycio M, Gribben JG, Stilgenbauer S, Buhler A, Kipps TJ, Purse B, Zhang J, De Bedout S, Mei J, Chanan-Khan A.

Leuk Lymphoma. 2016;57(6):1291-9. doi: 10.3109/10428194.2015.1128540. Epub 2016 Jan 14.

PMID:
26763349
31.

Activity of the CD40 antagonistic antibody lucatumumab - insights from CLL-niche mimicking xenografts and fludarabine combinations.

Stiefelhagen M, Gigel C, Vasyutina E, Möllmann M, Breuer A, Mayer P, Dürig J, Herling M.

Leuk Lymphoma. 2016 Sep;57(9):2235-8. doi: 10.3109/10428194.2015.1135433. Epub 2016 Jan 12. No abstract available.

PMID:
26758550
32.

Anemia and Mild Cognitive Impairment in the German General Population.

Dlugaj M, Winkler A, Weimar C, Dürig J, Broecker-Preuss M, Dragano N, Moebus S, Jöckel KH, Erbel R, Eisele L; Heinz Nixdorf Recall Study Investigative Group.

J Alzheimers Dis. 2016;49(4):1031-42. doi: 10.3233/JAD-150434.

PMID:
26599053
33.

Shorter telomeres correlate with an increase in the number of uniparental disomies in patients with chronic lymphocytic leukemia.

Sellmann L, Scholtysik R, de Beer D, Eisele L, Klein-Hitpass L, Nückel H, Dührsen U, Dürig J, Röth A, Baerlocher GM.

Leuk Lymphoma. 2016;57(3):590-5. doi: 10.3109/10428194.2015.1076929. Epub 2015 Oct 12.

PMID:
26457386
34.

Microwave, r0 Structural Parameters, Conformational Stability, and Vibrational Assignment of (Chloromethyl)fluorosilane.

Guirgis GA, Sawant DK, Brenner RE, Deodhar BS, Seifert NA, Geboes Y, Pate BH, Herrebout WA, Hickman DV, Durig JR.

J Phys Chem A. 2015 Nov 25;119(47):11532-47. doi: 10.1021/acs.jpca.5b06679. Epub 2015 Nov 13.

PMID:
26436757
35.

Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group.

Goede V, Bahlo J, Chataline V, Eichhorst B, Dürig J, Stilgenbauer S, Kolb G, Honecker F, Wedding U, Hallek M.

Leuk Lymphoma. 2016;57(4):789-96. doi: 10.3109/10428194.2015.1091933. Epub 2015 Oct 13.

PMID:
26377031
36.

Recurrent alterations of TNFAIP3 (A20) in T-cell large granular lymphocytic leukemia.

Johansson P, Bergmann A, Rahmann S, Wohlers I, Scholtysik R, Przekopowitz M, Seifert M, Tschurtschenthaler G, Webersinke G, Jäger U, Siebert R, Klein-Hitpass L, Dührsen U, Dürig J, Küppers R.

Int J Cancer. 2016 Jan 1;138(1):121-4. doi: 10.1002/ijc.29697. Epub 2015 Jul 30.

37.

Molecular spectroscopy and molecular structure - Selected communications presented at the 1st International Turkish Congress on Molecular Spectroscopy (TURCMOS 2013).

Durig JR, Fausto R, Ünsalan O, Bayarı S, Kuş N, Ildız GÖ.

Spectrochim Acta A Mol Biomol Spectrosc. 2016 Jan 5;152:523-4. doi: 10.1016/j.saa.2015.06.085. Epub 2015 Jun 24. No abstract available.

PMID:
26183526
38.

Multipotent Hematopoietic Progenitors Divide Asymmetrically to Create Progenitors of the Lymphomyeloid and Erythromyeloid Lineages.

Görgens A, Ludwig AK, Möllmann M, Krawczyk A, Dürig J, Hanenberg H, Horn PA, Giebel B.

Stem Cell Reports. 2015 Jul 14;5(1):154-155. doi: 10.1016/j.stemcr.2015.06.010. Epub 2015 Jul 14. No abstract available.

39.

R0 Structural parameters, conformational, vibrational studies and ab initio calculations of cyanocyclopentane.

Sawant DK, Klaassen JJ, Gounev TK, Durig JR.

Spectrochim Acta A Mol Biomol Spectrosc. 2015 Dec 5;151:468-79. doi: 10.1016/j.saa.2015.06.116. Epub 2015 Jun 30.

PMID:
26151436
40.

Functional abnormalities and changes in gene expression in fibroblasts and macrophages from the bone marrow of patients with acute myeloid leukemia.

Li Y, Dürig J, Göbel M, Hanoun M, Klein-Hitpaß L, Dührsen U.

Int J Hematol. 2015 Sep;102(3):278-88. doi: 10.1007/s12185-015-1833-x. Epub 2015 Jun 28.

PMID:
26121956
41.

Recurrent CDKN1B (p27) mutations in hairy cell leukemia.

Dietrich S, Hüllein J, Lee SC, Hutter B, Gonzalez D, Jayne S, Dyer MJ, Oleś M, Else M, Liu X, Słabicki M, Wu B, Troussard X, Dürig J, Andrulis M, Dearden C, von Kalle C, Granzow M, Jauch A, Fröhling S, Huber W, Meggendorfer M, Haferlach T, Ho AD, Richter D, Brors B, Glimm H, Matutes E, Abdel Wahab O, Zenz T.

Blood. 2015 Aug 20;126(8):1005-8. doi: 10.1182/blood-2015-04-643361. Epub 2015 Jun 11.

PMID:
26065650
42.

Microwave, structural, conformational, vibrational studies and ab initio calculations of fluoroacetyl chloride.

Deodhar BS, Brenner RE, Klaassen JJ, Tubergen MJ, Durig JR.

Spectrochim Acta A Mol Biomol Spectrosc. 2015 Sep 5;148:289-98. doi: 10.1016/j.saa.2015.04.007. Epub 2015 Apr 9.

PMID:
25909903
43.

Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma.

Mai EK, Bertsch U, Dürig J, Kunz C, Haenel M, Blau IW, Munder M, Jauch A, Schurich B, Hielscher T, Merz M, Huegle-Doerr B, Seckinger A, Hose D, Hillengass J, Raab MS, Neben K, Lindemann HW, Zeis M, Gerecke C, Schmidt-Wolf IG, Weisel K, Scheid C, Salwender H, Goldschmidt H.

Leukemia. 2015 Aug;29(8):1721-9. doi: 10.1038/leu.2015.80. Epub 2015 Mar 19.

PMID:
25787915
44.

Multipotent hematopoietic progenitors divide asymmetrically to create progenitors of the lymphomyeloid and erythromyeloid lineages.

Görgens A, Ludwig AK, Möllmann M, Krawczyk A, Dürig J, Hanenberg H, Horn PA, Giebel B.

Stem Cell Reports. 2014 Dec 9;3(6):1058-72. doi: 10.1016/j.stemcr.2014.09.016. Epub 2014 Oct 23. Erratum in: Stem Cell Reports. 2015 Jul 14;5(1):154-5. Stem Cell Reports. 2015 Jul 14;5(1):154-155.

45.

Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation.

Langerbeins P, Busch R, Anheier N, Dürig J, Bergmann M, Goebeler ME, Hurtz HJ, Stauch MB, Stilgenbauer S, Döhner H, Fink AM, Cramer P, Fischer K, Wendtner CM, Hallek M, Eichhorst B.

Am J Hematol. 2014 Dec;89(12):E239-43. doi: 10.1002/ajh.23841. Epub 2014 Sep 26.

46.

Ben van der Veken honor issue.

Durig J.

Spectrochim Acta A Mol Biomol Spectrosc. 2015 Feb 5;136 Pt A:1-2. doi: 10.1016/j.saa.2014.07.019. Epub 2014 Jul 14. No abstract available.

PMID:
25085211
47.

Conformational stability, r(0) structural parameters, vibrational assignments and ab initio calculations of ethyldichlorophosphine.

Darkhalil ID, Paquet C, Waqas M, Gounev TK, Durig JR.

Spectrochim Acta A Mol Biomol Spectrosc. 2015 Feb 5;136 Pt A:42-50. doi: 10.1016/j.saa.2014.01.039. Epub 2014 Jan 24.

PMID:
24618201
48.

Microwave, structural, conformational, vibrational studies and ab initio calculations of isocyanocyclopentane.

Durig JR, Klaassen JJ, Sawant DK, Deodhar BS, Panikar SS, Gurusinghe RM, Darkhalil ID, Tubergen MJ.

Spectrochim Acta A Mol Biomol Spectrosc. 2015 Feb 5;136 Pt A:3-15. doi: 10.1016/j.saa.2013.12.078. Epub 2013 Dec 28.

PMID:
24480667
49.

Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia.

Bergmann AK, Schneppenheim S, Seifert M, Betts MJ, Haake A, Lopez C, Maria Murga Penas E, Vater I, Jayne S, Dyer MJ, Schrappe M, Dührsen U, Ammerpohl O, Russell RB, Küppers R, Dürig J, Siebert R.

Genes Chromosomes Cancer. 2014 Apr;53(4):309-16. doi: 10.1002/gcc.22141. Epub 2014 Jan 21.

PMID:
24446122
50.

Expanded CD8+ T cells of murine and human CLL are driven into a senescent KLRG1+ effector memory phenotype.

Göthert JR, Eisele L, Klein-Hitpass L, Weber S, Zesewitz ML, Sellmann L, Röth A, Pircher H, Dührsen U, Dürig J.

Cancer Immunol Immunother. 2013 Nov;62(11):1697-1709.

PMID:
24022692

Supplemental Content

Support Center